Technology | October 27, 2014

FDA Clears Self-Expanding Peripheral Stent System

The thin, flexible stent is indicated for the iliac arteries that supply blood to the pelvis and legs

Everflex stent, Covidien, ev3

Oct. 27, 2014 — The U.S Food and Drug Administration (FDA) cleared the EverFlex Self-Expanding Peripheral Stent System. The stent was developed by ev3, which is now a part of Covidien.

The thin, flexible stent is indicated for the iliac arteries that supply blood to the pelvis and legs. The stent is an implant made of a nickel-titanium alloy (nitinol) tubing and laser cut into a mesh shape. The stent is mounted in a long, thin, tube-like device called the delivery

The FDA said generally, patients who are not suitable candidates for balloon angioplasty are also not suitable candidates for stent placement. The EverFlex Self-Expanding Peripheral Stent System should also not be used in patients who:

  • Have known allergies to the metals in the stent.
  • Have a blockage that will not allow complete inflation of the angioplasty balloon or proper placement of the stent.
  • Cannot take medicines that thin the blood or prevent blood clots.
  •  

?For more information: www.accessdata.fda.gov

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th